Allied Market Research
Loading...
0
New
New

Liquid Biopsy Market by Product & Service (Kits & Reagents, Platforms & Instruments, and Services), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [ctDNA], and Other Biomarkers), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, and Other Cancers), and End User (Hospitals & Laboratories and Government & Academic Research Centers): Global Opportunity Analysis and Industry Forecast, 2021–2028

A01561
Pages: 235
May 2021 | 17719 Views
   
Author(s) : Kishor Sherkar, Sumitra Choudhary
Tables: 159
Charts: 52
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Liquid Biopsy Market

Request Now !

Liquid Biopsy Market Overview:

The global liquid biopsy market size accounted for $1,204.2 million in 2020, and is estimated to reach $6,804.9 million by 2028, registering a CAGR of 20.9% from 2021 to 2028. 

Liquid biopsy is a convenient, fast, non-invasive, and reproducible sampling method that can reflect the changes in tumor gene expression profile, and provide a robust base for individualized therapy and early diagnosis of cancer. Moreover, screening early cancer, monitoring tumor progression, assessing therapeutic response & clinical prognosis, and detecting recurrent & refractory tumors is been focused on in the recent years. Furthermore, liquid biopsy has recently gained widespread attention as a non-invasive alternative technique to tissue biopsy in patients with cancer, due to technological advances regarding both feasibility and turnaround time.

Liquid-Biopsy--Market-2021-2028

Get more information on this report : Request Sample Pages

The coronavirus disease (COVID-19) has spread across the globe. Hence, governments have imposed several rules and lockdowns across the globe, owing to increase in number of corona virus patients, which has impacted the market growth in the initial phase of the forecast period. This has resulted in the suspension of early diagnosis programs. In addition, there has been a decrease in  screenings, visits, therapies, and surgeries related to cancer, with variation by cancer type and site of service globally resulting in increase of cancer morbidity and mortality in 2020. The pandemic has also impacted the logistics and supplies of cancer diagnostic raw materials and components and other essential commodities used in the production of liquid biopsy. These factors limit the growth of the liquid biopsy market during COVID-19 pandemic.

The liquid biopsy market is experiencing growth due to advancements such as next-generation sequencing for advanced cancer patients in liquid biopsies,  increase in number of cancer patients, and rise in patient preference for minimally invasive therapies. However, lack of awareness of liquid biopsy in the developing regions restricts to the market growth. On the contrary, increase in healthcare expenditure in the developing countries, such as India and China, and use of liquid biopsy tests to treat rare cancers are expected to present ample opportunities for market growth. 

Global Liquid Biopsy Market Segmentation  

The liquid biopsy market is categorized on the basis of product & service, cancer type, circulating biomarker, end user, and region. By product & service, it is divided into kits & reagents, platforms & instruments, and services. By cancer type, it is classified into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers. By circulating biomarker, it is categorized into circulating tumor cell, extracellular vesicle, circulating tumor DNA [ctDNA], and other biomarkers. By end user, it is classified into hospital & laboratory and government & research centers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

Segment Review

By product & service, the market is categorized into kits & reagent, platforms & instruments, and service. The platforms & instruments segment is expected to be the fastest growing segment during forecast period owing to large number of ongoing research & development of platforms & instrument and approvals in 2020. For instance in 20202020, Personalis, Inc. launched NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients. Further Guardant Health, Inc. is developing new precision oncology medicines GuardantINFORM platform with an extensive clinical-genomic liquid biopsy dataset of advanced cancer patients.

Liquid Biopsy Market
By Product & Service

Your browser does not support the canvas element.

Kits & Reagent segment holds a dominant position in 2020

Get more information on this report : Request Sample Pages

By circulating biomarker, the market is divided into circulating tumor cell, extracellular vesicle, circulating tumor DNA, and other biomarker. The circulating tumor cell segment generated the highest revenue in 2020 owing to increased number of clinically imperative tests with genomic analyses in recent years. Further, circulating tumor DNA is expected to be the fastest growing segment during the forecast period, owing to rapid development of next-generation sequencing (NGS) technologies in liquid biopsy advancements applied to circulating tumor DNA (ctDNA).

Liquid Biopsy Market
By Circulating Biomarker

Your browser does not support the canvas element.

Circulating Tumor DNA is the most lucrative segment during the forecast period

Get more information on this report : Request Sample Pages

By cancer type, the market is classified into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers. The lung cancer segment is anticipated to dominate the liquid biopsy market owing to increase in prevalence of non-small cell lung cancer form across the globe. For instance, as per the World Health Organization, lung cancer is by far the leading cause of cancer death among both men and women, estimated to have around 1.80 million deaths globally in 2020. Further, prostate cancer is expected to be the fastest growing segment during the forecast period as it is the most prevalent type of cancer and the second leading cause of death in North America.

Liquid Biopsy Market
By Cancer Type

Your browser does not support the canvas element.

Breast Cnacer is the most lucrative segment during the forecast period

Get more information on this report : Request Sample Pages

By end user, the market is bifurcated into hospitals & laboratories and government & academic research centers. The hospital & laboratory segment dominated the liquid biopsy market in 2020 attributed to wider usage of liquid biopsy tests across hospitals and laboratory settings which are the preferable healthcare facilities for patients.

Liquid Biopsy Market
By End User

Your browser does not support the canvas element.

Breast Cnacer is the most lucrative segment during the forecast period

Get more information on this report : Request Sample Pages

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In 2020, North America accounted for the highest contribution to the total revenue generated, owing to the presence of large key players such as Biocept, F. Hoffmann-La Roche AG, Qiagen N.V. and among others. In addition, high cancer prevalence and wider adoption of novel liquid-biopsy tests support the growth of the North America liquid biopsy market. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period. This is attributed  to rise in disposable income, increase in government initiatives to modernize healthcare infrastructure, and rise in healthcare expenditure. In addition, strategic approvals and partnerships between leading market players to promote liquid biopsy technology in this region is expected to boost the market growth.

Liquid Biopsy Market
By Region

2028
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 20.7% during 2020-2028.

Get more information on this report : Request Sample Pages

Prominent players operating in the global liquid biopsy market include Bio-Rad Laboratories, Inc, Biocept Inc., Guardant Health Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd. (FOUNDATION MEDICINE, INC.), Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V., and Thermo Fisher Scientific Inc.

Key Benefits For Stakeholders

  • This report entails a detailed quantitative analysis along with the current and future global liquid biopsy market trends from 2020 to 2028 to identify the prevailing opportunities along with strategic assessment.
  • The liquid biopsy market forecast is studied from 2021 to 2028. 
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the liquid biopsy market.

Key Market Segments

By Product & Service

  • Kits & Reagents
  • Platforms & Instruments
  • Services

By Circulating Biomarker

  • Circulating Tumor Cells
  • Extracellular Vesicles
  • Circulating Tumor DNA [ctDNA]
  • Other Biomarkers

By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Liver Cancer
  • Other Cancers  

By Region

  • North America
  • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Bargaining power of buyers
3.2.4.Bargaining power of suppliers
3.2.5.Thereat of new entrants
3.2.6.Threat of substitutes
3.2.7.Intensity of competitive rivalry

3.3.Top player positioning, 2020

3.1.Regulation
3.2.Market dynamics

3.2.1.Drivers

3.2.1.1.Rise in incidences and prevalence of various cancer types
3.2.1.2.Increase in demand for safe and non-invasive procedures
3.2.1.3.Advantages of liquid biopsy launches and technology

3.2.2.Restraints

3.2.2.1.Lack of awareness in developing and underdeveloped regions

3.2.3.Opportunities

3.2.3.1.Use of liquid biopsy for treatment of rare cancer
3.2.3.2.Untapped potential of emerging markets

3.3.Impact Analysis
3.4.Impact Analysis of the Covid-19 on Liquid Biopsy Market

CHAPTER 4:LIQUID BIOPSY MARKET, BY PRODUCT & SERVICES

4.1.Overview

4.1.1.Market size and forecast

4.2.Kits & Reagents

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market share analysis, by country

4.3.Platforms & Instruments

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market share analysis, by country

4.4.Services

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market share analysis, by country

CHAPTER 5:LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

5.1.Overview

5.1.1.Market size and forecast

5.2.Circulating Tumor Cell

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Circulating Tumor DNA

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Extracellular Vesicles

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Other Biomarkers

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

CHAPTER 6:LIQUID BIOPSY MARKET, BY CANCER TYPE

6.1.Overview

6.1.1.Market size and forecast

6.2.Lung Cancer

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Breast Cancer

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.5.Colorectal Cancer

6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country

6.6.Prostate cancer

6.6.1.Market size and forecast, by region
6.6.2.Market analysis, by country

6.7.Liver cancer

6.7.1.Market size and forecast, by region
6.7.2.Market analysis, by country

6.8.Other Cancers

6.8.1.Market size and forecast, by region
6.8.2.Market analysis, by country

CHAPTER 7:LIQUID BIOPSY MARKET, BY END USER

7.1.Overview

7.1.1.Market size and forecast

7.2.Hospital and Laboratory

7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country

7.3.Government and Academic Research Centers

7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country

CHAPTER 8:LIQUID BIOPSY MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast

8.2.North America

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.North America Liquid Biopsy Market, by Product & Service
8.2.3.North America Liquid Biopsy Market, by Circulating Biomarker
8.2.4.North America Liquid Biopsy Market, by Cancer Type
8.2.5.North America Liquid Biopsy Market, by End User
8.2.6.Market size and forecast, by country
8.2.7.U.S.

8.2.7.1.U.S. Liquid biopsy market, by Product & Service
8.2.7.2.U.S. Liquid biopsy market, by Circulating Biomarker
8.2.7.3.U.S. Liquid biopsy market, by Cancer Type
8.2.7.4.U.S. Liquid biopsy market, by End User

8.2.8.Canada

8.2.8.1.Canada Liquid biopsy market, by Product & Service
8.2.8.2.Canada Liquid biopsy market, by Circulating Biomarker
8.2.8.3.Canada Liquid biopsy market, by Cancer Type
8.2.8.4.Canada Liquid biopsy market, by End User

8.2.9.Mexico

8.2.9.1.Mexico Liquid biopsy market, by Product & Service
8.2.9.2.Mexico liquid biopsy market, by Circulating Biomarker
8.2.9.3.Mexico Liquid biopsy market, by Cancer Type
8.2.9.4.Mexico Liquid biopsy market, by End User

8.3.Europe

8.3.1.Key market trends, growth factors, and opportunities
8.3.3.Europe Market size and forecast, by Product & Service
8.3.4.Europe Market size and forecast, by Circulating Biomarker
8.3.5.Europe Market size and forecast, by Cancer Type
8.3.6.Europe Market size and forecast, by End User
8.3.7.Market size and forecast, by country
8.3.8.Germany

8.3.8.1.Germany Liquid biopsy market, by Product & Service
8.3.8.2.Germany Liquid Biopsy Market, by Circulating Biomarker
8.3.8.3.Germany Liquid Biopsy Market, by Cancer Type
8.3.8.4.Germany Liquid Biopsy Market, by End User

8.3.9.France

8.3.9.1.France Liquid biopsy market, by Product & Service
8.3.9.2.France Liquid Biopsy Market, by Circulating Biomarker
8.3.9.3.France Liquid Biopsy Market, by Cancer Type
8.3.9.4.France Liquid Biopsy Market, by End User

8.3.10.UK

8.3.10.1.UK Liquid biopsy market, by Product & Service
8.3.10.2.UK Liquid Biopsy Market, by Circulating Biomarker
8.3.10.3.UK Liquid Biopsy Market, by Cancer Type
8.3.10.4.UK Liquid Biopsy Market, by End User

8.3.11.Italy

8.3.11.1.Italy Liquid biopsy market, by Product & Service
8.3.11.2.Italy Liquid Biopsy Market, by Circulating Biomarker
8.3.11.3.Italy Liquid Biopsy Market, by Cancer Type
8.3.11.4.Italy Liquid Biopsy Market, by End User

8.3.12.Spain

8.3.12.1.Spain Liquid biopsy market, by Product & Service
8.3.12.2.Spain Liquid Biopsy Market, by Circulating Biomarker
8.3.12.3.Spain Liquid Biopsy Market, by Cancer Type
8.3.12.4.Spain Liquid Biopsy Market, by End User

8.3.13.Rest of Europe

8.3.13.1.Rest of Europe Liquid biopsy market, by Product & Service
8.3.13.2.Rest of Europe Liquid Biopsy Market, by Circulating Biomarker
8.3.13.3.Rest of Europe Liquid Biopsy Market, by Cancer Type
8.3.13.4.Rest of Europe Liquid Biopsy Market, by End User

8.4.Asia-Pacific

8.4.1.Key market trends and opportunities
8.4.2.Asia-Pacific Market size and forecast, by Product & Service
8.4.3.Asia-Pacific Market size and forecast, by Circulating Biomarker
8.4.4.Asia-Pacific Market size and forecast, by Cancer Type
8.4.5.Asia-Pacific Market size and forecast, by End User
8.4.6.Market size and forecast, by country
8.4.7.Japan

8.4.7.1.Japan Liquid Biopsy Market, by Product & Service
8.4.7.2.Japan Liquid Biopsy Market, by Circulating Biomarker
8.4.7.3.Japan Liquid Biopsy Market, by Cancer Type
8.4.7.4.Japan Liquid Biopsy Market, by End User

8.4.8.China

8.4.8.1.China Liquid Biopsy Market, by Product & Service
8.4.8.2.China Liquid Biopsy Market, by Circulating Biomarker
8.4.8.3.China Liquid Biopsy Market, by Cancer Type
8.4.8.4.China Liquid Biopsy Market, by End User

8.4.9.Australia

8.4.9.1.Australia Liquid Biopsy Market, by Product & Service
8.4.9.2.Australia Liquid Biopsy Market, by Circulating Biomarker
8.4.9.3.Australia Liquid Biopsy Market, by Cancer Type
8.4.9.4.Australia Liquid Biopsy Market, by End User

8.4.10.India

8.4.10.1.India Liquid Biopsy Market, by Product & Service
8.4.10.2.India Liquid Biopsy Market, by Circulating Biomarker
8.4.10.3.India Liquid Biopsy Market, by Cancer Type
8.4.10.4.India Liquid Biopsy Market, by End User

8.4.11.South Korea

8.4.11.1.South Korea Liquid Biopsy Market, by Product & Service
8.4.11.2.South Korea Liquid Biopsy Market, by Circulating Biomarker
8.4.11.3.South Korea Liquid Biopsy Market, by Cancer Type
8.4.11.4.South Korea Liquid Biopsy Market, by End User

8.4.12.Taiwan

8.4.12.1.Taiwan Liquid Biopsy Market, by Product & Service
8.4.12.2.Taiwan Liquid Biopsy Market, by Circulating Biomarker
8.4.12.3.Taiwan Liquid Biopsy Market, by Cancer Type
8.4.12.4.Taiwan Liquid Biopsy Market, by End User

8.4.13.Rest of Asia-Pacific

8.4.13.1.Rest of Asia-Pacific Liquid Biopsy Market, by Product & Service
8.4.13.2.Rest of Asia-Pacific Liquid Biopsy Market, by Circulating Biomarker
8.4.13.3.Rest of Asia-Pacific Liquid Biopsy Market, by Cancer Type
8.4.13.4.Rest of Asia-Pacific Liquid Biopsy Market, by End User

8.5.LAMEA

8.5.1.Key market trends, growth factors, and opportunities
8.5.3.LAMEA Market size and forecast, by Product & Service
8.5.4.LAMEA Market size and forecast, by Circulating Biomarker
8.5.5.LAMEA Market size and forecast, by Cancer Type
8.5.6.LAMEA Market size and forecast, by End User
8.5.7.Market size and forecast, by country
8.5.8.Brazil

8.5.8.1.Brazil Liquid Biopsy Market, by Product & Service
8.5.8.2.Brazil Liquid Biopsy Market, by Circulating Biomarker
8.5.8.3.Brazil Liquid Biopsy Market, by Cancer Type
8.5.8.4.Brazil Liquid Biopsy Market, by End User

8.5.9.Turkey

8.5.9.1.Turkey Liquid Biopsy Market, by Product & Service
8.5.9.2.Turkey Liquid Biopsy Market, by Circulating Biomarker
8.5.9.3.Turkey Liquid Biopsy Market, by Cancer Type
8.5.9.4.Turkey Liquid Biopsy Market, by End User

8.5.10.Saudi Arabia

8.5.10.1.Saudi Arabia Liquid Biopsy Market, by Product & Service
8.5.10.2.Saudi Arabia Liquid Biopsy Market, by Circulating Biomarker
8.5.10.3.Saudi Arabia Liquid Biopsy Market, by Cancer Type
8.5.10.4.Saudi Arabia Liquid Biopsy Market, by End User

8.5.11.South Africa

8.5.11.1.South Africa Liquid Biopsy Market, by Product & Service
8.5.11.2.South Africa Liquid Biopsy Market, by Circulating Biomarker
8.5.11.3.South Africa Liquid Biopsy Market, by Cancer Type
8.5.11.4.South Africa Liquid Biopsy Market, by End User

8.5.12.Rest of LAMEA

8.5.12.1.Rest of LAMEA Liquid Biopsy Market, by Product & Service
8.5.12.2.Rest of LAMEA Liquid Biopsy Market, by Circulating Biomarker
8.5.12.3.Rest of LAMEA Liquid Biopsy Market, by Cancer Type
8.5.12.4.Rest of LAMEA Liquid Biopsy Market, by End User

CHAPTER 9:COMPANY PROFILES

9.1.BIO-RAD LABORATORIES, INC.

9.1.1.1.Company overview
9.1.1.2.Company snapshot
9.1.1.3.Operating business segments
9.1.1.4.Product portfolio
9.1.1.5.Business performance
9.1.1.6.Key strategic moves and developments

9.2.BIOCEPT, INC.

9.2.1.1.Company overview
9.2.1.2.Company snapshot
9.2.1.3.Operating business segments
9.2.1.4.Product portfolio
9.2.1.5.Business performance
9.2.1.6.Key strategic moves and developments

9.3.GUARDANT HEALTH INC.

9.3.1.1.Company overview
9.3.1.2.Company snapshot
9.3.1.3.Operating business segments
9.3.1.4.Product portfolio
9.3.1.5.Business performance
9.3.1.6.Key strategic moves and developments

9.4.ILLUMINA, INC.

9.4.1.1.Company overview
9.4.1.2.Company snapshot
9.4.1.3.Operating business segments
9.4.1.4.Product portfolio
9.4.1.5.Business performance
9.4.1.6.Key strategic moves and developments

9.5.F. HOFFMANN-LA ROCHE LTD. (FOUNDATION MEDICINE, INC.)

9.5.1.1.Company overview
9.5.1.2.Company snapshot
9.5.1.3.Operating business segments
9.5.1.4.Product portfolio
9.5.1.5.Business performance
9.5.1.6.Key strategic moves and developments

9.6.JOHNSON & JOHNSON

9.6.1.1.Company overview
9.6.1.2.Company snapshot
9.6.1.3.Operating business segments
9.6.1.4.Product portfolio
9.6.1.5.Business performance

9.7.LABORATORY CORPORATION OF AMERICA HOLDINGS

9.7.1.1.Company overview
9.7.1.2.Company snapshot
9.7.1.3.Operating business segments
9.7.1.4.Product portfolio
9.7.1.5.Business performance
9.7.1.6.Key strategic moves and developments

9.8.MDXHEALTH SA

9.8.1.1.Company overview
9.8.1.2.Company snapshot
9.8.1.3.Operating business segments
9.8.1.4.Product portfolio
9.8.1.5.Business performance
9.8.1.6.Key strategic moves and developments

9.9.QIAGEN N.V.

9.9.1.1.Company overview
9.9.1.2.Company snapshot
9.9.1.3.Operating business segments
9.9.1.4.Product portfolio
9.9.1.5.Business performance
9.9.1.6.Key strategic moves and developments

9.10.THERMO FISHER SCIENTIFIC

9.10.1.1.Company overview
9.10.1.2.Company snapshot
9.10.1.3.Operating business segments
9.10.1.4.Product portfolio
9.10.1.5.Business performance
9.10.1.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2028 ($MILLION)
TABLE 02.LIQUID BIOPSY MARKET FOR KITS & REAGENTS, BY REGION, 2020-2028 ($MILLION)
TABLE 03.LIQUID BIOPSY MARKET FOR PLATFORMS & INSTRUMENTS, BY REGION, 2020-2028 ($MILLION)
TABLE 04.LIQUID BIOPSY MARKET FOR SERVICES, BY REGION, 2020-2028 ($MILLION)
TABLE 05.LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 06.LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELL, BY REGION, 2020–2028 ($MILLION)
TABLE 07.LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2020–2028 ($MILLION)
TABLE 08.LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2020–2028 ($MILLION)
TABLE 09.LIQUID BIOPSY MARKET FOR OTHERS, FOR OTHER BIOMARKERS, BY REGION, 2020–2028 ($MILLION)
TABLE 10.LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 11.LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 12.LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 13.LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 14.LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 15.LIQUID BIOPSY MARKET FOR LIVER CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 16.LIQUID BIOPSY MARKET FOR OTHER CANCER, BY REGION, 2020–2028 ($MILLION)
TABLE 17.LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 18.LIQUID BIOPSY MARKET FOR HOSPITAL AND LABORATORY, BY REGION, 2020–2028 ($MILLION)
TABLE 19.LIQUID BIOPSY MARKET FOR GOVERNMENT AND ACADEMIC RESEARCH CENTER, BY REGION, 2020–2028 ($MILLION)
TABLE 20.LIQUID BIOPSY MARKET REVENUE, BY REGION, 2020–2028 ($MILLION)
TABLE 21.NORTH AMERICA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 22.NORTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 23.NORTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 24.NORTH AMERICA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 25.NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 26.U.S. LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 27.U.S. LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 28.U.S. LIQUID BIOPSY MARKET, BY CANCER TYPE , 2020–2028 ($MILLION)
TABLE 29.U.S. LIQUID BIOPSY MARKET, BY END USER , 2020–2028 ($MILLION)
TABLE 30.CANADA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 31.CANADA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 32.CANADA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 33.CANADA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 34.MEXICO LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 35.MEXICO LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 36.MEXICO. LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 37.MEXICO. LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 38.EUROPE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 39.EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 40.EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 41.EUROPE LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 42.EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 43.GERMANY LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 44.GERMANY LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 45.GERMANY LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 46.GERMANY LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 47.FRANCE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 48.FRANCE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 49.FRANCE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 50.FRANCE LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 51.UK LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 52.UK LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 53.UK LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 54.UK LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 55.ITALY LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 56.ITALY LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 57.ITALY LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 58.ITALY LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 59.SPAIN LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 60.SPAIN LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 61.SPAIN LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 62.SPAIN LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 63.REST OF EUROPE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 64.REST OF EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 65.REST OF EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 66.REST OF EUROPE LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 67.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 68.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 69.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 70.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 71.ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 72.JAPAN LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 73.JAPAN LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 74.JAPAN LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 75.JAPAN LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 76.CHINA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 77.CHINA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 78.CHINA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 79.CHINA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 80.AUSTRALIA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 81.AUSTRALIA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 82.AUSTRALIA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 83.AUSTRALIA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 84.INDIA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 85.INDIA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 86.INDIA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 87.INDIA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 88.SOUTH KOREA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 89.SOUTH KOREA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 90.SOUTH KOREA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 91.SOUTH KOREA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 92.TAIWAN LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 93.TAIWAN LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 94.TAIWAN LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 95.TAIWAN LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 96.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 97.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 98.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 99.REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 100.LAMEA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 101.LAMEA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 102.LAMEA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 103.LAMEA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 104.LAMEA LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 105.BRAZIL LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 106.BRAZIL LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 107.BRAZIL LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 108.BRAZIL LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 109.TURKEY LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 110.TURKEY LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 111.TURKEY LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 112.TURKEY LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 113.SAUDI ARABIA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 114.SAUDI ARABIA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 115.SAUDI ARABIA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 116.SAUDI ARABIA LIQUID BIOPSY MARKET, BY END USER, 2020–2028($MILLION)
TABLE 117.SOUTH AFRICA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 118.SOUTH AFRICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 119.SOUTH AFRICA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 120.SOUTH AFRICA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 121.REST OF LAMEA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2028 ($MILLION)
TABLE 122.REST OF LAMEA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2028 ($MILLION)
TABLE 123.REST OF LAMEA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2020–2028 ($MILLION)
TABLE 124.REST OF LAMEA LIQUID BIOPSY MARKET, BY END USER, 2020–2028 ($MILLION)
TABLE 125.BIO-RAD: COMPANY SNAPSHOT
TABLE 126.MYRIAD: OERATING SEGMENT
TABLE 127.BIO-RAD: PRODUCT PORTFOLIO
TABLE 128.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 129.BIOCEPT: COMPANY SNAPSHOT
TABLE 130.BIOCEPT: PRODUCT PORTFOLIO
TABLE 131.BIOCEPT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132.GUARDANT: COMPANY SNAPSHOT
TABLE 133.GUARDANT: OPERATING SEGMENTS
TABLE 134.GUARDANT: PRODUCT PORTFOLIO
TABLE 135.BIOCEPT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 136.ILLUMINA: COMPANY SNAPSHOT
TABLE 137.ILLUMINA: OPERATING SEGMENTS
TABLE 138.ILLUMINA: PRODUCT PORTFOLIO
TABLE 139.ROCHE: COMPANY SNAPSHOT
TABLE 140.ROCHE: OPERATING SEGMENTS
TABLE 141.ROCHE: PRODUCT PORTFOLIO
TABLE 142.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 143.J&J: COMPANY SNAPSHOT
TABLE 144.J&J: OPERATING BUSINESS SEGMENTS
TABLE 145.J&J: PRODUCT PORTFOLIO
TABLE 146.LABCORP: COMPANY SNAPSHOT
TABLE 147.LABCORP: OPERATING SEGMENTS
TABLE 148.LABCORP: PRODUCT PORTFOLIO
TABLE 149.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 150.MDXHEALTH: COMPANY SNAPSHOT
TABLE 151.MDXHEALTH: PRODUCT PORTFOLIO
TABLE 152.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 153.QIAGEN: COMPANY SNAPSHOT
TABLE 154.QIAGEN: PRODUCT PORTFOLIO
TABLE 155.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 156.THERMO: COMPANY SNAPSHOT
TABLE 157.THERMO: OPERATING SEGMENTS
TABLE 158.THERMO: PRODUCT PORTFOLIO
TABLE 159.THERMO: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.GLOBAL LIQUID BIOPSYMARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.PIE CHART FOR CANCER CASES DIAGNOSED IN 2020
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF LIQUID BIOPSY MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020 & 2028 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF LIQUID BIOPSY MARKET FOR PLATFORMS & INSTRUMENTS, BY COUNTRY, 2020 & 2028 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF LIQUID BIOPSY MARKET FOR SERVICES, BY COUNTRY, 2020 & 2028 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELL,  BY COUNTRY, 2020 & 2028 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2020 & 2028 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES,  BY COUNTRY, 2020 & 2028 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR OTHER BIOMARKERS, BY COUNTRY,  2020 & 2028 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR LIVER CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR OTHER CANCER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR HOSPITAL AND LABORATORY, BY COUNTRY, 2020 & 2028 (%)
FIGURE 27.COMPARATIVE ANALYSIS OF LIQUID BIOPSY MARKET FOR GOVERNMENT AND ACADEMIC RESEARCH CENTER, BY COUNTRY, 2020 & 2028 (%)
FIGURE 28.BIO-RAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.BIO-RAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.BIO-RAD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31.BIOCEPT: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.GUARDANT: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.GUARDANT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.GUARDANT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35.ILLUMINA: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.ILLUMINA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.ILLUMINA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 ($MILLION)
FIGURE 40.J&J: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42.J&J: REVENUE SHARE BY REGION, 2020(%)
FIGURE 43.LABCORP: REVENUE, 2018–2020 ($MILLION)
FIGURE 44.LABCORP: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 45.LABCORP: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 46.MDXHEALTH: NET SALES, 2018–2020 ($MILLION)
FIGURE 47.MDXHEALTH: REVENUE SHARE BY REGION, 2020(%)
FIGURE 48.QIAGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 49.QIAGEN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50.THERMO: NET SALES, 2018–2020 ($MILLION)
FIGURE 51.THERMO: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 52.THERMO: REVENUE SHARE, BY REGION, 2020 (%)

 
 

The liquid biopsy tests have gained popularity as an efficient, non-invasive alternative to solid tissue biopsies for cancer treatment. At present, liquid biopsy tests are used for molecular and diagnostic characterization of tumor fragments and agents, such as circulating biomarkers, which include circulating tumor cells, circulating tumor Deoxyribonucleic acid (DNA), extracellular vesicles, and others released into the blood of cancer patients. These tests are anticipated to manage and treat patients with rare cancers and help improve their survival rates in the near future. Further, improved diagnostic testing, increase in awareness among the population regarding cancer, and surge in launches of liquid biopsy diagnostic devices and multicenter early detection test devices are further anticipated to provide growth opportunities and increase the adoption rate of liquid biopsy tests such as next-generation sequencing companion diagnostic test. Liquid biopsies have positively impacted cancer diagnostics, therapeutics, and treatment. 

Rise in number of cancer cases has led to an increase in number of therapies to treat cancer, resulting in an increase in the need for prognostic and diagnostic tests, especially liquid biopsies. These tests serve this purpose by predicting the best approach for cancer treatment, understanding the molecular characteristics of the cancer, predicting the probability of cancer recurrence, and improving the patient stratification along with real-time monitoring of therapies. Increase in number of healthcare professionals have preferred these tests to choose the appropriate cancer therapy and understand the onset of the disease. Liquid biopsies are expected to help improve the patient survival rate and reduce the cost of treatment for cancer patients, owing to the help provided in prediction of the drug therapeutic targets. 

The liquid biopsy market is highest in North America, owing to the increase in adoption of this test in the region, higher awareness about the benefits among the healthcare providers, and increase in disposable income among patients. Although the use of liquid biopsies in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase, owing to rise in disposable income and government initiatives in the developing countries, such as China and India, to improve the care provided to the patients and contribute toward market growth. Thus, the Asia-Pacific and LAMEA regions are expected to offer lucrative growth opportunities to the key players in the industry.
 

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. Top companies such as, F. Hoffmann-La Roche Ltd., Qiagen N.V, Biocept Inc., Guardant Health Inc., and Illumina, Inc. has garnered the maximum market share in 2020. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. circulating tumor DNA segment segment is the most influencing segment This is attributed due to an rapid development of next-generation sequencing (NGS) technologies applied to circulating tumor DNA (ctDNA).

A. The major factor that fuels the growth of the global liquid biopsy market includesThe advantages of implementing liquid biopsies are expected to boost the growth of the market. Also, minimal invasiveness and metastatic relapse evaluation, are expected to increase the demand for these tests. Surge in prevalence of cancer cases, and patient preference for minimally invasive therapies are anticipated to fuel the market growthtechnological advancement to ease and simply the process of thawing, and rise in launches and agreement of liquid biopsy . In addition, rise in awareness and government initiative towards the plasma donation and increase in number of embryo donors and rise in awareness of third party reproduction.

A. Asia-Pacific has the highest growth rate in the market which is growing this is attributed due to Asia-Pacific have a large patient pool with a rise in disposable income, increase in government initiatives to modernize healthcare infrastructure, and rise in healthcare expenditureAn increase in the number of chronic diseases that lead to organ failures is expected to boost the demand for thawed blood.

A. Liquid biopsies are non-invasive blood tests that detect tumor DNA & RNA fragments and circulating tumor cells (CTCs), which are released into the blood from the primary tumors and metastatic sites

A. Liquid biopsy is a simple and precise alternative to surgical biopsies, which allows physicians & surgeons to detect & treat cancer at an early stage and acquire tumor information through blood samples. These biopsies are particularly significant as they help the physician understand the molecular changes and dynamics of cancer. Moreover, cancer recurrence is expected to be understood through well-timed liquid biopsies.

A. The total market value of liquid biopsy market is $1,204.2 million in 2020

A. The forcast period for liquid biopsy market is 2020 to 2028

A. The market value of liquid biopsy market in 2028 is $6,804.9 million

A. The base year is 2020 in liquid biopsy market

Allied Market Research Allied Market Research Allied Market Research

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Liquid Biopsy Market

  • Online Only
  • $3,654
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,060
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,078
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,821
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,512
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers